Winning comes naturally to GXPi
11 September 2013 | By Three Thinking Co.
Regulatory compliance specialist GXPi has announced the appointment of Richard Winning...
List view / Grid view
11 September 2013 | By Three Thinking Co.
Regulatory compliance specialist GXPi has announced the appointment of Richard Winning...
11 September 2013 | By AstraZeneca
AstraZeneca and Merck & Co Inc, announced a worldwide licensing agreement for Merck’s oral small molecule inhibitor of WEE1 kinase (MK-1775)...
11 September 2013 | By Gilead Sciences
Gilead Sciences, Inc. has submitted a NDA to the U.S. FDA for approval of idelalisib, an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of iNHL...
11 September 2013 | By Amgen
Study links RAS mutations to Vectibix clinical response in patients with metastatic colorectal cancer...
10 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the completion of patient enrolment for a Phase IIa clinical trial...
10 September 2013 | By GlaxoSmithKline
GSK and Theravance, Inc. announced that the PADAC to the US FDA voted 11 yes to 2 no that the efficacy and safety data provide substantial evidence to support approval of umeclidinium/vilanterol...
9 September 2013 | By Catalent Pharma Solutions
Catalent Pharma Solutions has named David Heyens in the new role of President of Catalent Asia Pacific...
9 September 2013 | By Merck
Merck announced that the NDA for its investigational fertility treatment, corifollitropin alfa, has been accepted for standard review by the U.S. FDA...
9 September 2013 | By Biogen Idec
Biogen Idec and Isis Pharmaceuticals, Inc. announced that the companies have entered into a broad, multi-year collaboration...
9 September 2013 | By Boehringer Ingelheim
Data from two 48 week Phase III studies involving more than 3,000 patients...
9 September 2013 | By
In patients with symptomatic asthma despite moderate-dose maintenance ICS therapy, the addition of tiotropium Respimat® significantly improves lung function and provides sustained bronchodilation over 24 hours.1
9 September 2013 | By Boehringer Ingelheim
TIOSPIR™, with over 17,000 COPD patients included and one of the largest international COPD trials ever conducted...
9 September 2013 | By Merck
Merck and Maccabi Healthcare Services are starting a new, multi-year agreement...
8 September 2013 | By Novartis
Novartis announced new analyses of data for once-daily Ultibro® Breezhaler®...
6 September 2013 | By Takeda
FDA has granted Priority Review status for the Biologics License Application (BLA) for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis...